Ecnoglutide
InvestigationalA long-acting GLP-1 receptor agonist developed by Sciwind Biosciences. A Phase 3 obesity trial showed 13.2% weight loss at 40 weeks with once-weekly dosing. Primarily targeting China and Asian markets with potential for global expansion.
XW003 · Sciwind GLP-1
6 human studies
- Preclinical
- 40%
- Clinical
- 60%
Based on 10 cited sources
clinically demonstrated · moderate confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 91 (1A35/1B21/1C14/1D14/1E7): meta-analysis of 4 RCTs (41937314, N=1643, Cochrane RoB-2) plus ≥2 independent double-blind placebo-controlled phase 3 RCTs — obesity (40555243, N=664) and T2D EECOH-1 (41501026, N=211) — a phase 2 RCT (39333121) and phase 1/discovery (37364710); pooled human N well over 1,000 with direct population/route/ outcome match. Mechanism 95 (2A38/2B28/2C19/2D10): GLP-1R is a validated class target, ecnoglutide has measured binding plus functional cAMP-biased agonism, full target→cAMP→insulin/satiety pathway, monotonic dose-response across 0.6–2.4 mg in human in-vivo trials. Plausibility 97 (3A38/3B25/3C20/ 3D14): full mechanism→surrogate(HbA1c)→clinical(weight/glycaemia) chain proven, fully coherent with incretin biology, multiple same-class agents confirm the effect (head-to-head non-inferiority/marginal superiority vs dulaglutide in EECOH-2 40854315), tightly scoped GLP-1R claim. Global Coverage 43 (4A14/4B11/4C13/4D5): pivotal trials all Sciwind-sponsored and China-only across many centres but one country/cluster; ~11 indexed studies; independent meta-analysis/editorial add limited external scrutiny; investigational (CT.gov-registered, not yet approved). Community Experience 11 (5A3/5B3/5C0/5D5): no meaningful documented real-world use, no consumer track record, only trial-derived GI signal. Effectiveness basis clinical (moderate): obesity phase 3 −13.2% bodyweight (Δ −13.3% vs placebo; 87% vs 16% achieving ≥5% loss) far exceeds the ~5% MCID on a hard patient-relevant outcome; superior to placebo and non-inferior to dulaglutide in T2D, though no obesity head-to-head and ~13% trails best-in-class semaglutide/ tirzepatide; confidence moderate given high-quality but China-only data.
How It Works (Simplified)
Ecnoglutide (XW003) is a long-acting GLP-1 receptor agonist designed for once-weekly subcutaneous injection. It mimics the incretin hormone GLP-1 to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion. Developed by Sciwind Biosciences, it represents China’s entry into the competitive GLP-1 obesity therapeutics market.
Scientific Pathways
GLP-1 Receptor Activation: Like other GLP-1 receptor agonists, ecnoglutide binds to and activates GLP-1 receptors in the pancreas, brain, and GI tract. This triggers multiple downstream effects: enhanced insulin secretion (glucose-dependent), suppressed glucagon release, delayed gastric emptying, and central satiety signaling in the hypothalamus.
Engineering for Duration: Ecnoglutide incorporates structural modifications to resist DPP-4 enzymatic degradation and extend half-life, enabling once-weekly dosing comparable to semaglutide.
Clinical Evidence
Phase 3 Weight Loss Data: A Phase 3 trial conducted in Chinese adults with overweight or obesity (without diabetes) demonstrated 13.2% body weight reduction at 40 weeks with ecnoglutide at the highest dose (2.4 mg once weekly), versus essentially no change on placebo. The efficacy is competitive with first-generation weekly GLP-1 agonists, though direct head-to-head comparisons against other obesity agents are not yet available.
Glycemic Control: Phase 3 data also showed significant HbA1c reduction in patients with type 2 diabetes, supporting potential dual indications for obesity and diabetes.
Safety Profile
The safety profile is consistent with the GLP-1 receptor agonist class, with gastrointestinal adverse events (nausea, vomiting, diarrhea) as the most common side effects. No unique safety signals beyond the established GLP-1 class effects have been reported. Safety data is primarily from Chinese patient populations; global generalizability awaits broader trials.
Important Limitations
- Phase 3 data primarily from Chinese populations; global applicability uncertain
- No FDA submission planned in the near term
- Weight loss (13.2% at 40 weeks) trails leading competitors (semaglutide ~15-17%, tirzepatide ~20-26%)
- No head-to-head trials against established GLP-1 therapies
- Not available outside clinical trials in China
- Limited English-language publication of trial data
Semaglutide
AvoidBoth are GLP-1 receptor agonists. Co-administration would provide redundant GLP-1 agonism with increased risk of GI adverse events.
Tirzepatide
AvoidBoth target GLP-1 receptors. Combining would create overlapping mechanisms with increased adverse event risk.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Ecnoglutide
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium · NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191 · hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833 · NN9838
A long-acting amylin analog developed by Novo Nordisk for weight management. Studied in Phase 3 trials as CagriSema (combination with semaglutide). The Phase 3 REDEFINE 1 trial showed -20.4% weight loss with cagrilintide-semaglutide versus -3.0% with placebo at 68 weeks.
CagriSema
Cagrilintide-Semaglutide · NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.